About This Trial
An International Phase 3 Randomized, Double-blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis
- Status: Enrolling now
- Location: Miami Valley Hospital
- Study type: Interventional
- Ages eligible for study: 18 to 50 years
- Genders eligible for study: Female
- Principal Investigator: Dr. Michael Galloway
- For more information about this study, visit ClinicalTrials.gov: NCT03204331
Contact Us
If you would like information about participating in this study, contact:
Dawn Shields, BS
937-208-3689
dashields@premierhealth.com